Abstract
It has long been accepted that high concentrations of glutamate can destroy neurons,and this is the basis of the theory of excitotoxicity during brain injury such as stroke.Glutamate N-methyl- D-aspartate (NMDA)receptor antagonists such as Selfotel,Aptiganel,Gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.The failure of these agents has been attributed to poor studies in animal models and to poorly designed clinical trials.We also speculate that NMDA receptor anatagonism may have hindered endogenous mechanisms for neuronal survival and neuroregeneration.It remains to be proven in human stroke whether NMDA receptor antagonism can be neuroprotective.
Keywords: Ischemic Stroke, D-aspartate, glutamate, Aptiganel
Current Molecular Medicine
Title: The Rise and Fall of NMDA Antagonists for Ischemic Stroke
Volume: 4 Issue: 2
Author(s): L. Hoyte, P. A. Barber, A. M. Buchan and M. D. Hill
Affiliation:
Keywords: Ischemic Stroke, D-aspartate, glutamate, Aptiganel
Abstract: It has long been accepted that high concentrations of glutamate can destroy neurons,and this is the basis of the theory of excitotoxicity during brain injury such as stroke.Glutamate N-methyl- D-aspartate (NMDA)receptor antagonists such as Selfotel,Aptiganel,Gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.The failure of these agents has been attributed to poor studies in animal models and to poorly designed clinical trials.We also speculate that NMDA receptor anatagonism may have hindered endogenous mechanisms for neuronal survival and neuroregeneration.It remains to be proven in human stroke whether NMDA receptor antagonism can be neuroprotective.
Export Options
About this article
Cite this article as:
Hoyte L., Barber A. P., Buchan M. A. and Hill D. M., The Rise and Fall of NMDA Antagonists for Ischemic Stroke, Current Molecular Medicine 2004; 4 (2) . https://dx.doi.org/10.2174/1566524043479248
DOI https://dx.doi.org/10.2174/1566524043479248 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibiting the Enzymes of the Endothelin and Renin-Angiotensin Systems in Cancer
Current Enzyme Inhibition Glutamate as a Modulator of Embryonic and Adult Neurogenesis
Current Topics in Medicinal Chemistry Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neuro-Hormonal Regulation of Immune and Metabolic Function
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Formulation and Standardization of Anti-acne Herbal Foaming Face Wash using <i>Curcuma longa</i> along with <i>Aloe vera, Rosa centifolia</i>, and <i>Cit - rus sinensis</i>
Drug Delivery Letters Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design Cellular Protection and Therapeutic Potential of Tocotrienols
Current Pharmaceutical Design Strategies to Create a Regenerating Environment for the Injured Spinal Cord
Current Pharmaceutical Design Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Synthetic Cathinones: A New Public Health Problem
Current Neuropharmacology Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Altering the Sphingosine-1-Phosphate/Ceramide Balance: A Promising Approach for Tumor Therapy
Current Pharmaceutical Design Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design NLRP3 Inflammasome in the Pathophysiology of Hemorrhagic Stroke: A Review
Current Neuropharmacology The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology